Beneficio clínico y económico de 32 años de tratamiento antirretroviral de personas que viven con VIH en España: ¿ha sido una intervención eficiente?

Introduction: Although antiretroviral therapy (ART) for HIV / AIDS was introduced in 1987, improvementin disease progression and reduction in mortality at a population level was not observed until 1996, withthe combination of three or more drugs. The objective was to estimate the clinical and econom...

Descripción completa

Detalles Bibliográficos
Autores: Pérez Elías, María Jesús, Podzamczer Palter, Daniel, Ventayol Bosch, Pere, Jarrín, Inmaculada, Castro, Antonio, Rubio Rodríguez, Darío, Rubio Terrés, Carlos
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/196116
Acceso en línea:https://hdl.handle.net/2445/196116
Access Level:acceso abierto
Palabra clave:Antiretrovirals
Malalts de sida
Antiretroviral agents
AIDS patients
id ES_03c3bf19fa2b936df65ee3c31c4adaa0
oai_identifier_str oai:recercat.cat:2445/196116
network_acronym_str ES
network_name_str España
repository_id_str
spelling Beneficio clínico y económico de 32 años de tratamiento antirretroviral de personas que viven con VIH en España: ¿ha sido una intervención eficiente?Pérez Elías, María JesúsPodzamczer Palter, DanielVentayol Bosch, PereJarrín, InmaculadaCastro, AntonioRubio Rodríguez, DaríoRubio Terrés, CarlosAntiretroviralsMalalts de sidaAntiretroviral agentsAIDS patientsIntroduction: Although antiretroviral therapy (ART) for HIV / AIDS was introduced in 1987, improvementin disease progression and reduction in mortality at a population level was not observed until 1996, withthe combination of three or more drugs. The objective was to estimate the clinical and economic benefitof ART in Spain in the 32-year period between 1987 and 2018. Methods: A cost-benefit analysis was performed, using a second-order Monte Carlo simulation, from the societal (base case) and the National Health System (NHS) perspectives. New cases of HIV, AIDS and related deaths were obtained from the SINIVIH and UNAIDS registries, with population projections without ART using triple exponential smoothing. Expenditure on ART was obtained from the National AIDS Plan reports and market studies. Results: The NHS invested 6,185 million euros in 32 years. In that period, 323,651 AIDS-related deaths, 500,129 AIDS cases and 161,417 HIV cases were averted, with total savings of 41,997 million euros. The net benefit (net savings) is estimated at 35,812 million euros (societal) and 1,032 million euros (NHS). For every euro invested in ART, a return on investment of (sic) 6.79 and (sic) 1.16 was obtained, respectively. Conclusion: The use of ART over 32 years prevented a large number of deaths and cases of AIDS and HIV, providing significant economic savings for the NHS. ART is an efficient intervention for the NHS. (c) 2021 The Author(s). Published by Elsevier Espana, S.L.U. on behalf of Sociedad Espanola de Enfermedades Infecciosas y Microbiologia Clinica.Elsevier BV2023202320222023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion7 p.application/pdfhttps://hdl.handle.net/2445/196116Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.1016/j.eimc.2021.05.006Enfermedades Infecciosas y Microbiología Clínica, 2022, vol. 40, num. 10, p. 550-556https://doi.org/10.1016/j.eimc.2021.05.006cc by (c) Pérez Elías, Maria Jesús et al., 2021http://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccessoai:recercat.cat:2445/1961162026-05-29T05:05:01Z
dc.title.none.fl_str_mv Beneficio clínico y económico de 32 años de tratamiento antirretroviral de personas que viven con VIH en España: ¿ha sido una intervención eficiente?
title Beneficio clínico y económico de 32 años de tratamiento antirretroviral de personas que viven con VIH en España: ¿ha sido una intervención eficiente?
spellingShingle Beneficio clínico y económico de 32 años de tratamiento antirretroviral de personas que viven con VIH en España: ¿ha sido una intervención eficiente?
Pérez Elías, María Jesús
Antiretrovirals
Malalts de sida
Antiretroviral agents
AIDS patients
title_short Beneficio clínico y económico de 32 años de tratamiento antirretroviral de personas que viven con VIH en España: ¿ha sido una intervención eficiente?
title_full Beneficio clínico y económico de 32 años de tratamiento antirretroviral de personas que viven con VIH en España: ¿ha sido una intervención eficiente?
title_fullStr Beneficio clínico y económico de 32 años de tratamiento antirretroviral de personas que viven con VIH en España: ¿ha sido una intervención eficiente?
title_full_unstemmed Beneficio clínico y económico de 32 años de tratamiento antirretroviral de personas que viven con VIH en España: ¿ha sido una intervención eficiente?
title_sort Beneficio clínico y económico de 32 años de tratamiento antirretroviral de personas que viven con VIH en España: ¿ha sido una intervención eficiente?
dc.creator.none.fl_str_mv Pérez Elías, María Jesús
Podzamczer Palter, Daniel
Ventayol Bosch, Pere
Jarrín, Inmaculada
Castro, Antonio
Rubio Rodríguez, Darío
Rubio Terrés, Carlos
author Pérez Elías, María Jesús
author_facet Pérez Elías, María Jesús
Podzamczer Palter, Daniel
Ventayol Bosch, Pere
Jarrín, Inmaculada
Castro, Antonio
Rubio Rodríguez, Darío
Rubio Terrés, Carlos
author_role author
author2 Podzamczer Palter, Daniel
Ventayol Bosch, Pere
Jarrín, Inmaculada
Castro, Antonio
Rubio Rodríguez, Darío
Rubio Terrés, Carlos
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv Antiretrovirals
Malalts de sida
Antiretroviral agents
AIDS patients
topic Antiretrovirals
Malalts de sida
Antiretroviral agents
AIDS patients
description Introduction: Although antiretroviral therapy (ART) for HIV / AIDS was introduced in 1987, improvementin disease progression and reduction in mortality at a population level was not observed until 1996, withthe combination of three or more drugs. The objective was to estimate the clinical and economic benefitof ART in Spain in the 32-year period between 1987 and 2018. Methods: A cost-benefit analysis was performed, using a second-order Monte Carlo simulation, from the societal (base case) and the National Health System (NHS) perspectives. New cases of HIV, AIDS and related deaths were obtained from the SINIVIH and UNAIDS registries, with population projections without ART using triple exponential smoothing. Expenditure on ART was obtained from the National AIDS Plan reports and market studies. Results: The NHS invested 6,185 million euros in 32 years. In that period, 323,651 AIDS-related deaths, 500,129 AIDS cases and 161,417 HIV cases were averted, with total savings of 41,997 million euros. The net benefit (net savings) is estimated at 35,812 million euros (societal) and 1,032 million euros (NHS). For every euro invested in ART, a return on investment of (sic) 6.79 and (sic) 1.16 was obtained, respectively. Conclusion: The use of ART over 32 years prevented a large number of deaths and cases of AIDS and HIV, providing significant economic savings for the NHS. ART is an efficient intervention for the NHS. (c) 2021 The Author(s). Published by Elsevier Espana, S.L.U. on behalf of Sociedad Espanola de Enfermedades Infecciosas y Microbiologia Clinica.
publishDate 2022
dc.date.none.fl_str_mv 2022
2023
2023
2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/196116
url https://hdl.handle.net/2445/196116
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1016/j.eimc.2021.05.006
Enfermedades Infecciosas y Microbiología Clínica, 2022, vol. 40, num. 10, p. 550-556
https://doi.org/10.1016/j.eimc.2021.05.006
dc.rights.none.fl_str_mv cc by (c) Pérez Elías, Maria Jesús et al., 2021
http://creativecommons.org/licenses/by/3.0/es/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc by (c) Pérez Elías, Maria Jesús et al., 2021
http://creativecommons.org/licenses/by/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 7 p.
application/pdf
dc.publisher.none.fl_str_mv Elsevier BV
publisher.none.fl_str_mv Elsevier BV
dc.source.none.fl_str_mv Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869402748966928384
score 15,812429

Similares en LA Referencia